Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Villa-Álvarez M, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, López-Soto A, Payer AR, Gonzalez-Garcia E, Huergo-Zapico L, Gonzalez S.

Oncoimmunology. 2017 Jul 20;6(10):e1353856. doi: 10.1080/2162402X.2017.1353856. eCollection 2017.

2.

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.

Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660. [Epub ahead of print]

PMID:
29115891
3.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

4.

Non-coding recurrent mutations in chronic lymphocytic leukaemia.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E.

Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22.

PMID:
26200345
5.

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV; Spanish Myeloma Group (GEM/PETHEMA).

Haematologica. 2015 Sep;100(9):1207-13. doi: 10.3324/haematol.2015.128439. Epub 2015 Jun 11.

6.

Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients.

Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, Gonzalez ME, Payer AR, Alonso-Garcia A, Rodriguez-Villar D, Dominguez-Iglesias F, Sancho JM.

Leuk Lymphoma. 2015 Jun 18:1-4. [Epub ahead of print] No abstract available.

PMID:
25976108
7.

On the prediction of Hodgkin lymphoma treatment response.

deAndrés-Galiana EJ, Fernández-Martínez JL, Luaces O, Del Coz JJ, Fernández R, Solano J, Nogués EA, Zanabilli Y, Alonso JM, Payer AR, Vicente JM, Medina J, Taboada F, Vargas M, Alarcón C, Morán M, González-Ordóñez A, Palicio MA, Ortiz S, Chamorro C, Gonzalez S, González-Rodríguez AP.

Clin Transl Oncol. 2015 Aug;17(8):612-9. doi: 10.1007/s12094-015-1285-z. Epub 2015 Apr 21.

PMID:
25895906
8.

Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.

Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Gonzalez ME, Rubio-Castro A, Dominguez-Iglesias F, Solano J, Alonso-Nogues E, Fernandez-Alvarez C, Zanabili Y, Alonso JM, Payer AR, Vicente JM, Medina J, Sancho JM.

Leuk Lymphoma. 2015;56(11):3096-102. doi: 10.3109/10428194.2015.1038709. Epub 2015 May 12.

PMID:
25860241
9.

Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.

Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, Fernandez-Guizan A, Payer AR, López-Soto A, Gonzalez S.

Biomed Res Int. 2014;2014:265840. doi: 10.1155/2014/265840. Epub 2014 Sep 17.

10.

Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.

Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, Contesti J, Gonzalez-García E, Payer AR, Villa-Alvarez M, Fernández-Guizán A, López-Soto A, Gonzalez S.

PLoS One. 2014 Oct 6;9(10):e108326. doi: 10.1371/journal.pone.0108326. eCollection 2014.

11.

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.

Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S.

Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. No abstract available.

12.

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.

Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N.

Blood. 2014 Jun 12;123(24):3790-6. doi: 10.1182/blood-2013-12-543306. Epub 2014 Apr 29.

13.

Lenalidomide and chronic lymphocytic leukemia.

González-Rodríguez AP, Payer AR, Acebes-Huerta A, Huergo-Zapico L, Villa-Alvarez M, Gonzalez-García E, Gonzalez S.

Biomed Res Int. 2013;2013:932010. doi: 10.1155/2013/932010. Epub 2013 Sep 19. Review.

14.

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.

Villamor N, Conde L, Martínez-Trillos A, Cazorla M, Navarro A, Beà S, López C, Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Giné E, González-Díaz M, Hernández JM, Colado E, Payer AR, Rayon C, Navarro B, José Terol M, Bosch F, Quesada V, Puente XS, López-Otín C, Jares P, Pereira A, Campo E, López-Guillermo A.

Leukemia. 2013 Apr;27(5):1100-6. doi: 10.1038/leu.2012.357. Epub 2012 Dec 6.

PMID:
23295735
15.

PHF6 mutations in adult acute myeloid leukemia.

Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A.

Leukemia. 2011 Jan;25(1):130-4. doi: 10.1038/leu.2010.247. Epub 2010 Oct 29.

16.
17.

Trisomy 10 in acute myeloid leukemia: report of a new case.

Luño E, Payer AR, Luengo JR, Del Castillo TB, Garcia VP.

Cancer Genet Cytogenet. 1998 Jan 1;100(1):84-7.

PMID:
9406587

Supplemental Content

Loading ...
Support Center